ESC Heart Failure Guidelines 2026: What Patients Need to Know
Heart failure care has changed dramatically over the past decade. New medications, less invasive procedures and innovative monitoring technologies are giving healthcare teams more ways to help people live well with heart failure and maintain a good quality of life.
The 2026 European Society of Cardiology (ESC) Heart Failure Guidelines, presented at ESC Congress 2026 in Munich, reflect these advances. They place a strong emphasis on earlier diagnosis, personalised care and ensuring that patients receive the right treatment at the right time.
For many people, a diagnosis of heart failure can feel worrying or overwhelming. The reassuring news is that there are now more treatment options than ever before. Modern medications, minimally invasive procedures, specialist monitoring and multidisciplinary care are helping many patients manage their condition successfully for years.
In this article, we explain the most important updates from the 2026 ESC Heart Failure Guidelines and what they may mean for patients and families.
Key Takeaways
The most important messages for patients
- The new guidelines place greater emphasis on preventing heart failure and identifying it earlier.
- Heart failure classification has been simplified, helping to create clearer treatment pathways.
- Modern heart failure care increasingly combines medications, procedures, devices and specialist support.
- Mitral TEER with MitraClip has a strengthened role for selected patients with heart failure and significant mitral valve leakage.
- TAVI remains an important treatment for people with severe aortic stenosis, which can contribute to heart failure symptoms.
- Advanced therapies such as LVADs, such as HeartMate 3, may help carefully selected patients with advanced heart failure.
- Remote monitoring, including CardioMEMS, may help healthcare teams identify worsening heart failure earlier and support patients at home.
Why the 2026 ESC Heart Failure Guidelines Matter
The overarching theme of the 2026 guidelines is that heart failure should be recognised and treated as early as possible. Rather than focusing solely on people with established symptoms, the guidelines encourage healthcare professionals to identify risk factors, detect problems sooner and intervene before heart failure becomes more severe.
The ESC has adopted a staging approach that covers the entire patient journey, from people who are at risk of developing heart failure through to those with advanced disease who require specialist support.
For patients, this reflects a growing understanding that heart failure often develops gradually over many years. Earlier recognition may create opportunities to optimise treatment and maintain quality of life for longer.
Earlier Diagnosis and Prevention: A Major Shift in Focus
Many people who develop heart failure have underlying conditions that place extra strain on the heart, including:
- High blood pressure
- Coronary artery disease
- Diabetes
- Obesity
- Heart valve disease
The 2026 guidelines highlight the importance of identifying and managing these conditions before heart failure develops or progresses.
What This Means for You
It can be easy to dismiss symptoms as part of getting older. Breathlessness, reduced stamina, or swollen ankles may develop gradually and be hard to notice at first.
However, if you experience:
- Increasing shortness of breath
- Unusual tiredness
- Swelling in your ankles or legs
- Difficulty performing activities you previously managed comfortably
- It is important to discuss these symptoms with your healthcare team.
- Early assessment can make a significant difference.
Heart Failure Classification Has Been Simplified
Doctors often assess heart failure using a measurement called left ventricular ejection fraction (LVEF), which describes how much blood the heart pumps out with each heartbeat.
Previous ESC guidelines divided heart failure into three categories. The 2026 update simplifies this into two groups:
- Heart failure with reduced ejection fraction (LVEF below 50%)
- Heart failure with preserved ejection fraction (LVEF 50% or higher)
The previous category known as "heart failure with mildly reduced ejection fraction" has been removed because evidence suggests these patients often respond similarly to those with reduced ejection fraction.
Why This Change Matters
This update is designed to simplify diagnosis and treatment decisions.
Most patients are unlikely to notice any immediate change in their care. However, a clearer classification system may help ensure that treatment pathways are easier for healthcare teams to follow and implement.
Modern Heart Failure Care Is About More Than Medication
While medications remain the foundation of heart failure treatment, the 2026 guidelines recognise that many patients may also benefit from procedures, devices and specialist interventions.
The ESC now describes treatment using three broad categories:
- Foundational medical therapy
- Additional medical therapy
- Guideline-directed interventional therapy
This reflects the reality that heart failure care is becoming increasingly personalised.
Today, treatment plans often involve a multidisciplinary team that may include heart failure specialists, imaging experts, valve specialists, specialist nurses and, when appropriate, cardiac surgeons.
Medication Updates Patients Should Know About
Several medication recommendations have been strengthened in the 2026 guidelines.
One important update is the stronger recommendation for mineralocorticoid receptor antagonists (MRAs), including medicines such as spironolactone and eplerenone, across chronic heart failure regardless of ejection fraction.
The guidelines also include recommendations supporting consideration of semaglutide or tirzepatide in selected patients with heart failure with preserved ejection fraction and obesity.
What This Means for Patients
Guideline updates do not automatically mean that your medication needs to change. However, if you are living with heart failure, they provide a useful reason to review your treatment with your healthcare team and discuss whether your current management remains aligned with the latest evidence.
Mitral TEER: Treating a Leaky Mitral Valve Without Open-Heart Surgery
One of the most important procedure-related updates in the new guidelines is the strengthened role of Mitral Transcatheter Edge-to-Edge Repair (Mitral TEER).
What Is Mitral TEER?
Mitral TEER is a minimally invasive procedure used to treat significant mitral regurgitation, often described as a leaky mitral valve. Instead of open-heart surgery, doctors insert a catheter through a blood vessel and use a small device to help the valve close more effectively.
Who May Benefit?
Mitral TEER may be considered for some patients who:
- Have heart failure
- Have significant secondary mitral regurgitation
- Continue to experience symptoms despite appropriate medical treatment
- Are not considered ideal candidates for surgery
The 2026 guidelines upgrade their recommendations for Mitral TEER based on growing evidence supporting its use in carefully selected patients.
Why It Matters
Mitral TEER is not suitable for everyone. A specialist Heart Team makes decisions after carefully reviewing each patient's valve anatomy, symptoms, heart function, and overall health.
For suitable patients, reducing severe valve leakage may improve symptoms and quality of life while reducing the strain placed on the heart.
A Typical Patient Scenario
A patient with heart failure may continue to experience breathlessness despite receiving recommended medications. Tests reveal significant mitral valve leakage contributing to their symptoms. In this situation, the Heart Team may consider whether Mitral TEER could form part of the treatment plan.
TAVI and Heart Failure: Understanding the Connection
Heart valve disease and heart failure are closely linked.
Aortic stenosis, one of the most common heart valve conditions, occurs when the aortic valve becomes narrowed and restricts blood flow out of the heart.
As the condition progresses, it can cause:
- Breathlessness
- Fatigue
- Reduced exercise tolerance
- Symptoms that overlap with heart failure
What Is TAVI?
Transcatheter Aortic Valve Implantation (TAVI) is a minimally invasive procedure that replaces a severely narrowed aortic valve without conventional open-heart surgery. Navitor TAVI System is one of the technologies available for this treatment in the UK and Ireland.
Who May Benefit?
Patients with severe symptomatic aortic stenosis may be assessed by a specialist Heart Team to determine whether TAVI is appropriate.
Why Is TAVI Relevant to Heart Failure?
Sometimes symptoms that appear to be caused by heart failure are actually driven, at least in part, by severe valve disease.
As valve assessment becomes more integrated into heart failure services, potentially treatable valve conditions are more likely to be identified.
For suitable patients, treating severe aortic stenosis can play an important role in improving symptoms and daily functioning.
What Is an LVAD?
A Left Ventricular Assist Device (LVAD) is a mechanical pump that helps the heart circulate blood around the body. One of these devices is HeartMate3 LVAD.
What Has Changed?
The 2026 guidelines strengthen recommendations for durable mechanical circulatory support in selected patients with advanced heart failure.
Who Might Be Considered?
Patients who experience:
- Severe symptoms despite treatment
- Repeated hospital admissions
- Progressive limitation of everyday activities
- Advanced heart failure requiring specialist support<
may be referred to a dedicated advanced heart failure centre.
Why This Matters
LVAD therapy is highly specialised and not appropriate for every patient. However, advances in technology mean that it is becoming an increasingly important option for carefully selected individuals, either while awaiting transplantation or as longer-term therapy.
Telemonitoring and CardioMEMS: Supporting Patients at Home
Another important development highlighted in the guidelines is the growing role of remote monitoring.
The aim is straightforward: identify signs of worsening heart failure before symptoms become severe enough to require hospital treatment.
Remote care may include:
- Home blood pressure monitoring
- Weight monitoring
- Symptom tracking
- Telephone consultations
- Video appointments
- Connected monitoring devices
What Is CardioMEMS?
CardioMEMS is a small wireless sensor implanted into the pulmonary artery, the blood vessel that carries blood from the heart to the lungs. The device measures pressure changes within the circulation and transmits this information to the clinical team.
These changes may occur before a patient notices worsening symptoms, potentially allowing earlier treatment adjustments.
Who May Benefit?
CardioMEMS may be considered in selected patients with chronic heart failure, particularly those who have experienced previous hospital admissions and require closer monitoring.
What This Means for Patients
Many people find reassurance in knowing that their condition can be monitored between appointments.
While remote monitoring does not replace regular medical care, it may help healthcare teams detect potential problems earlier and provide support before symptoms become more serious.
Putting Patients at the Centre of Care
One of the most welcome aspects of the 2026 ESC Heart Failure Guidelines is the continued emphasis on patient education, self-care and shared decision-making.
Today, heart failure management is about much more than prescribing medication.
Patients are increasingly encouraged to understand:
- Their diagnosis
- Their treatment options
- The purpose of their medications
- Symptoms that may require medical attention
- Lifestyle measures that support heart health
The ESC has also updated its patient version of the guidelines to support people living with heart failure and encourage active participation in their care.
Questions to Ask Your Healthcare Team
If you are living with heart failure, these questions may help guide discussions with your specialist team:
- What is causing my heart failure?
- What is my ejection fraction and what does it mean?
- Is my current treatment aligned with the latest guidance?
- Could heart valve disease be contributing to my symptoms?
- Would a specialist Heart Team assessment be helpful?
- Could Mitral TEER be an option for me?
- If I have aortic stenosis, am I suitable for TAVI?
- Would remote monitoring benefit me?
- Are there any advanced therapies I should know about?
- What can I do to maintain the best possible quality of life?
The Bottom Line
The 2026 ESC Heart Failure Guidelines reflect how rapidly heart failure care continues to evolve. They promote earlier diagnosis, personalised treatment and a team-based approach that combines medications, procedures, devices and ongoing support.
Perhaps the most reassuring message for patients is that more treatment options are available than ever before. From modern medicines and minimally invasive procedures such as Mitral TEER and TAVI, to remote monitoring technologies and advanced therapies for severe disease, heart failure care continues to move forward.
Not every treatment will be right for every person, and guideline updates do not mean that everyone's care needs to change. However, they do highlight the value of regular follow-up, open conversations with your healthcare team and making sure you understand the options available to you.
If you are living with heart failure or have a heart valve condition that may affect your heart function, the updated guidance offers a reassuring reminder that progress continues to be made. Working closely with your healthcare team remains the best way to find an approach that is right for you.
- References
- Køber L, Adamo M, et al. 2026 ESC Guidelines for the Management of Heart Failure. European Heart Journal, 2026.
- European Society of Cardiology. Major Changes Made to the ESC Guidelines on Heart Failure. ESC Congress 2026.
- European Society of Cardiology. 2026 ESC Guidelines for the Management of Heart Failure: Congress Summary.
MAT-2679904 v1.0